Brought to you by 
Serenex gets a Phase II candidate from Mucosal Therapeutics
18 Jun 2014
Executive Summary
Cancer company Serenex licensed worldwide development and commercialization rights to an oral mucositis treatment from Mucosal Therapeutics LLC (drugs for aphthous lesions).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serenex gets a Phase II candidate from Mucosal Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice